Effect of magnesium carbonate on the solubility, dissolution and oral bioavailability of fenofibric acid powder as an alkalising solubilizer.

about

Effect of magnesium carbonate on the solubility, dissolution and oral bioavailability of fenofibric acid powder as an alkalising solubilizer.

Item

http://www.wikidata.org/entity/Q51434591

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Effect of magnesium carbonate ...... as an alkalising solubilizer.

@en

Effect of magnesium carbonate ...... as an alkalising solubilizer.

@nl

type

Item

label

Effect of magnesium carbonate ...... as an alkalising solubilizer.

@en

Effect of magnesium carbonate ...... as an alkalising solubilizer.

@nl

prefLabel

Effect of magnesium carbonate ...... as an alkalising solubilizer.

@en

Effect of magnesium carbonate ...... as an alkalising solubilizer.

@nl

P1476

Effect of magnesium carbonate ...... as an alkalising solubilizer.

@en

P2093

Chul Soon Yong

http://www.w3.org/2001/XMLSchema#string

Dong Shik Kim

http://www.w3.org/2001/XMLSchema#string

Dong Wuk Kim

http://www.w3.org/2001/XMLSchema#string

Dong Xun Li

http://www.w3.org/2001/XMLSchema#string

Han-Gon Choi

http://www.w3.org/2001/XMLSchema#string

Jeong Hyun Kim

http://www.w3.org/2001/XMLSchema#string

Jong Oh Kim

http://www.w3.org/2001/XMLSchema#string

Jong Soo Woo

http://www.w3.org/2001/XMLSchema#string

Kwan Hyung Cho

http://www.w3.org/2001/XMLSchema#string

Kyeong Soo Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Fenofibrate - a potential systemic treatment for diabetic retinopathy?

Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia

Prevention and treatment of diabetic retinopathy: evidence from large, randomized trials. The emerging role of fenofibrate.

Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement

Real-time endpoint monitoring and determination for a pharmaceutical salt formation process with in-line FT-IR spectroscopy.

An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes

Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.

Fenofibrate: treatment of hyperlipidemia and beyond.

Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.

Application of Box-Behnken design in the preparation and optimization of fenofibrate-loaded self-microemulsifying drug delivery system (SMEDDS).

P2888

s12272-015-0701-9

P304

531-538

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12272-015-0701-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26992922

http://www.w3.org/2001/XMLSchema#string

P921

Béésh Łikoní